Viatris Closes $36.50-a-Share Cash Buyout of Pacira BioSciences
Viatris completed its $36.50-per-share cash buyout of Pacira BioSciences on Nov. 17. What shareholders get, the delisting and the revenue outlook.

Viatris Inc. has completed its purchase of Pacira BioSciences, a maker of non-opioid pain treatments, paying $36.50 per share in cash, the Pittsburgh-based healthcare company said on Nov. 17. Pacira is now a wholly owned subsidiary of Viatris, and its stock will be delisted from the Nasdaq Global Select Market.
Pacira shareholders who did not tender their stock still get paid. Their shares were converted into the right to receive the same $36.50 per share, according to the company.
How the tender offer ended
Viatris first announced the deal on Oct. 8, 2026, and structured it as a tender offer, a direct bid to buy shares from stockholders at a fixed price. The offer expired one minute after 11:59 p.m. Eastern Time on Nov. 16, 2026.
Equiniti Trust Company, the depositary handling the offer, told Viatris that about 32,929,780 shares were validly tendered and not withdrawn. That is about 66.46% of Pacira’s outstanding shares at the deadline. With all conditions met or waived on Nov. 17, Peach Purchaser Sub Inc., a Viatris subsidiary created for the deal, accepted all of those shares for payment. The $36.50 is paid net of applicable withholding taxes and without interest.
A merger without a shareholder vote
After the tender offer closed, the Viatris subsidiary merged into Pacira, which survives as the company inside Viatris. The merger used Section 251(h) of Delaware’s General Corporation Law, which lets a buyer complete the second step of a deal like this without a vote of the target’s stockholders once the tender offer succeeds. The two-step structure blurs the usual line between a merger and an acquisition.
The total value of the transaction was not stated in the completion announcement.
What it means for shareholders and patients
For Pacira (Nasdaq: PCRX) investors, the deal turns their stock into cash at $36.50 a share, and the shares will stop trading once the Nasdaq delisting takes effect. Viatris (Nasdaq: VTRS) shareholders now own a business the company describes as a leader in non-opioid pain management.
Viatris expects Pacira to add total revenues of between $90 million and $100 million for the rest of 2026, covering Nov. 17 through Dec. 31, 2026.
Chief Executive Scott A. Smith tied the purchase to the company’s plan to strengthen its U.S. innovative medicines business. He said combining the two portfolios would let Viatris take “a leadership position in non-opioid pain management” and welcomed Pacira employees to the company. Viatris did not say whether the deal would bring job changes at Pacira.
Viatris sells generics, established brands and innovative medicines, and has global centers in Pittsburgh, Shanghai and Hyderabad, India. In its announcement, the company listed risks that could keep it from realizing the expected benefits of the Pacira deal, including business disruption and changes in customer relationships after the acquisition.
Sources: PR Newswire, BioSpace



